Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02136888
Recruitment Status : Completed
First Posted : May 13, 2014
Last Update Posted : May 13, 2014
Sponsor:
Information provided by (Responsible Party):
Actelion

Brief Summary:
The aim of this study is to demonstrate that therapeutic and supratherapeutic plasma exposures to ponesimod do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern as measured by the QTc (interval from beginning of the Q wave until end of the T wave corrected for heart rate) interval duration after administration of multiple oral doses of 40 mg and 100 mg to healthy male and female subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ponesimod Placebo Drug: Moxifloxacin Placebo Drug: Ponesimod 10 mg Drug: Ponesimod 20 mg Drug: Ponesimod 40 mg Drug: Ponesimod 60 mg Drug: Ponesimod 80 mg Drug: Ponesimod 100 mg Drug: Moxifloxacin 400 mg Phase 1

Detailed Description:

This is a Phase 1, single-center, double-blind, randomized, placebo and positive-controlled, double-dummy, parallel group, multiple-dose, up-titration study of the electrocardiographic effects of ponesimod in healthy male and female subjects with a nested cross-over comparison between moxifloxacin and placebo.

Subjects will be randomly assigned to Group A (ponesimod treatment group) or Group B (placebo treatment group) in a 1:1 ratio. Subjects in Group B will be further randomized in a 1:1 ratio to one of the following sequences: 400 mg moxifloxacin followed by moxifloxacin-matching placebo or moxifloxacin matching placebo followed by 400 mg moxifloxacin.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: A Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group, Multiple-dose, Up-titration Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects
Study Start Date : August 2011
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Arm Intervention/treatment
Experimental: Group A

Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).

Placebo matched for ponesimod will be given on Day −1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24.

Drug: Ponesimod Placebo
Drug: Moxifloxacin Placebo
Drug: Ponesimod 10 mg
Other Name: ACT-128800

Drug: Ponesimod 20 mg
Other Name: ACT-128800

Drug: Ponesimod 40 mg
Other Name: ACT-128800

Drug: Ponesimod 60 mg
Other Name: ACT-128800

Drug: Ponesimod 80 mg
Other Name: ACT-128800

Drug: Ponesimod 100 mg
Other Name: ACT-128800

Experimental: Group B
Placebo matched for ponesimod will be administered orally, once daily on Day −1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
Drug: Ponesimod Placebo
Drug: Moxifloxacin Placebo
Drug: Moxifloxacin 400 mg



Primary Outcome Measures :
  1. Baseline-adjusted, placebo-corrected effect on QTc interval (time interval from beginning of the Q wave until end of the T wave (ΔΔQTc interval)) on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of ΔΔQTc interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  2. Baseline-adjusted, placebo-corrected effect on QTc interval (time interval from beginning of the Q wave until end of the T wave (ΔΔQTc interval)) on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of ΔΔQTc interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.


Secondary Outcome Measures :
  1. Baseline-adjusted, placebo-corrected effect on QT beat-to-beat interval (QTbtb interval) on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of QTbtb interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  2. Baseline-adjusted, placebo-corrected effect on QT beat-to-beat interval (QTbtb interval) on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of QTbtb interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  3. Baseline-adjusted, placebo-corrected effect on heart rate on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of heart rate will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  4. Baseline-adjusted, placebo-corrected effect on heart rate on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of heart rate will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  5. Baseline-adjusted, placebo-corrected effect on the R-to-R interval (interval from the peak of one QRS complex to the peak of the next (RR interval)) on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of RR interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  6. Baseline-adjusted, placebo-corrected effect on the R-to-R interval (interval from the peak of one QRS complex to the peak of the next (RR interval)) on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of RR interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  7. Baseline-adjusted, placebo-corrected effect on the PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of PR interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  8. Baseline-adjusted, placebo-corrected effect on the PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of PR interval will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  9. Baseline-adjusted, placebo-corrected effect on QRS duration (time interval from the beginning of the Q wave to the end of the S wave) on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of QRS duration will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  10. Baseline-adjusted, placebo-corrected effect on QRS duration (time interval from the beginning of the Q wave to the end of the S wave) on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of QRS duration will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  11. Frequency of T-wave morphology changes on Day 12 (after 5 days of 40 mg ponesimod) [ Time Frame: 12 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of T-wave morphology changes will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 12.

  12. Frequency of T-wave morphology changes on Day 23 (after 5 days of 100 mg ponesimod) [ Time Frame: 23 Days ]
    Replicate electrocardiograms (ECGs) (at least 3 and up to 10) for the determination of T-wave morphology changes will be extracted from the continuous digital 12-lead ECG recording within 20 minutes prior to dosing and then at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours (total of 13 time points) post-dose on Days −1, 1, and 23.

  13. Change in systolic blood pressure from baseline up to end of study [ Time Frame: 31 Days ]
    Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.

  14. Change in diastolic blood pressure from baseline up to end of study [ Time Frame: 31 Days ]
    Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.

  15. Change in heart rate from baseline up to end of study [ Time Frame: 31 Days ]
    Heart rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand). Measurements should be recorded from the subject in the supine position after having rested for a 5-minute period.

  16. Change in QTc interval according to Bazett's correction (QTcB interval) from baseline up to end of study [ Time Frame: 31 Days ]
    QTcB interval will be determined from standard 12-lead ECG recordings. The QTcB interval is the QT interval corrected for heart rate with Bazett's formula (QTcB = QT/RR^0.5 where RR is 60/heart rate)

  17. Change in QTc interval according to Fridericia's correction (QTcF interval) from baseline up to end of study [ Time Frame: 31 Days ]
    QTcF interval will be determined from standard 12-lead ECG recordings. The QTcF interval is the QT interval corrected for heart rate with Fridericia's formula (QTcB = QT/RR^0.5 where RR is 60/heart rate)

  18. Change in forced expiratory volume in 1 second (FEV1) from baseline to end of study [ Time Frame: 31 Days ]
    FEV1 will be measured according to the American Thoracic Society/European Respiratory Society guidelines. Three good test breaths will be measured; the highest FEV1 value will be recorded. The spirometry device must be calibrated and the assessor trained.

  19. Change in forced vital capacity (FVC) from baseline to end of study [ Time Frame: 31 Days ]
    FVC will be measured according to the American Thoracic Society/European Respiratory Society guidelines. Three good test breaths will be measured; the highest FVC value will be recorded. The spirometry device must be calibrated and the assessor trained.

  20. Incidence of treatment emergent pulmonary function test decreases of >30% from baseline up to end of study [ Time Frame: 31 Days ]
    Pulmonary function tests will be performed according to the American Thoracic Society/European Respiratory Society guidelines. Three good test breaths will be measured; the highest values will be recorded. The spirometry device must be calibrated and the assessor trained.

  21. Area under the plasma concentration-time curve of ponesimod from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  22. Maximum plasma concentration (Cmax) of ponesimod after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  23. Time to maximum plasma concentration (tmax) of ponesimod after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.

  24. Trough plasma concentration of ponesimod on Days 5, 8, 16, and 19 (Ctrough) [ Time Frame: 19 Days ]
    Plasma concentrations of ponesimod will be measured on Days 5, 8, 16, and 19 immediately before administration of the study drug.The measured individual plasma concentrations will be used to directly obtain Ctrough.

  25. Area under the plasma concentration-time curve of the ponesimod metabolite ACT-204426 from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  26. Maximum plasma concentration (Cmax) of the ponesimod metabolite ACT-204426 after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  27. Time to maximum plasma concentration (tmax) of the ponesimod metabolite ACT-204426 after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.

  28. Area under the plasma concentration-time curve of the ponesimod metabolite ACT-338375 from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  29. Maximum plasma concentration (Cmax) of the ponesimod metabolite ACT-338375 after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  30. Time to maximum plasma concentration (tmax) of the ponesimod metabolite ACT-338375 after 5 days of dosing with 40 mg ponesimod [ Time Frame: 12 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 12 (after 5 days of dosing with 40 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.

  31. Area under the plasma concentration-time curve of ponesimod from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  32. Maximum plasma concentration (Cmax) of ponesimod after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  33. Time to maximum plasma concentration (tmax) of ponesimod after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ponesimod will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.

  34. Area under the plasma concentration-time curve of the ponesimod metabolite ACT-204426 from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  35. Maximum plasma concentration (Cmax) of the ponesimod metabolite ACT-204426 after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  36. Time to maximum plasma concentration (tmax) of the ponesimod metabolite ACT-204426 after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-204426 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.

  37. Area under the plasma concentration-time curve of the ponesimod metabolite ACT-338375 from time zero over the dosing interval (τ) (AUCτ) after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). AUCτ will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).

  38. Maximum plasma concentration (Cmax) of the ponesimod metabolite ACT-338375 after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain Cmax.

  39. Time to maximum plasma concentration (tmax) of the ponesimod metabolite ACT-338375 after 5 days of dosing with 100 mg ponesimod [ Time Frame: 23 Days ]
    Plasma concentrations of ACT-338375 will be measured at pre-dose and at 1, 2, 2.5, 3, 4, 5, 6, 8, 9, 10, 11, and 12 hours post-dose on Day 23 (after 5 days of dosing with 100 mg ponesimod). The measured individual plasma concentrations will be used to directly obtain tmax.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure.
  • Body mass index between 18.0 and 30.0 kg/m^2 (inclusive) at screening.
  • Healthy on the basis of medical history and the assessments performed at screening.
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to the first drug administration.
  • Systolic blood pressure between 90 and 150 mmHg and diastolic blood pressure between 50 and 90 mmHg.
  • 12-lead electrocardiogram (ECG) and 24-hour Holter ECG, without clinically relevant abnormalities at screening.
  • Hematology and clinical chemistry test results not deviating from the normal range to a clinically relevant extent at screening.
  • Negative results from urine drug screen at screening.
  • Ability to communicate well with the investigator and to understand and comply with the requirements of the study.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Known hypersensitivity to moxifloxacin or to any excipients of the drug formulations.
  • Veins unsuitable for intravenous puncture on either arm.
  • Treatment with another investigational drug within 3 months prior to screening.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drugs.
  • Smoking within 3 months prior to screening.
  • Any immunosuppressive treatment within 6 weeks before study drug administration.
  • Previous treatment with any prescribed or over-the-counter medications within 2 weeks prior to screening or five half-lives of the drug, whichever is longer.
  • Donation of blood, plasma or platelets within 3 months prior to screening or donations made on more than two occasions within the 12 months preceding the first dose administration.
  • Lymphopenia (< 1,000 cells/μL^9).
  • Viral, systemic, fungal, bacterial or protozoal infection within 4 weeks before the first study drug administration.
  • History or clinical evidence suggestive of active or latent tuberculosis at screening.
  • Positive hepatitis B surface antigen or hepatitis C antibody tests at screening.
  • Positive results from human immunodeficiency virus serology at screening.
  • FEV1 or FVC < 80% of the predicted value, or FEV1/FVC ratio < 0.7 at screening.
  • History of asthma or chronic obstructive pulmonary disease.
  • History of atrioventricular block on ECG.
  • Any cardiac condition or illness (including ECG abnormalities based on standard 12-lead ECG or on 24-hour Holter ECG at screening) with a potential to increase the cardiac risk of the subject or that may affect QTc interval analysis.
  • QTc interval > 450 milliseconds or > 470 milliseconds for male or female subjects, respectively (using the ECG machine heart rate correction method) at screening.
  • Heart rate < 50 beats per minute (bpm) at screening or Day -1 pre-dose on 12-lead ECG.
  • Subjects with personal or family history of long QT syndrome or hypokalemia.
  • History of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • History or presence of macular edema.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Legal incapacity or limited legal capacity at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02136888


Locations
Layout table for location information
United States, Indiana
Covance Clinical Research Unit (CRU)
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
Actelion
Investigators
Layout table for investigator information
Study Director: Patrick Brossard, PhD Actelion

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT02136888     History of Changes
Other Study ID Numbers: AC-058-110
First Posted: May 13, 2014    Key Record Dates
Last Update Posted: May 13, 2014
Last Verified: May 2014

Keywords provided by Actelion:
Ponesimod
Safety

Additional relevant MeSH terms:
Layout table for MeSH terms
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs